Collection of Blood Specimens for Circulating Tumor Cell Analysis
NCT ID: NCT01943500
Last Updated: 2017-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
14 participants
OBSERVATIONAL
2013-09-30
2016-08-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collection of Blood From Patients With Cancer
NCT00034216
Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients
NCT02904135
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663
Circulating Tumor Cells in Solid Tumors
NCT03161821
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer or no prior history of cancer
Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent obtained
* Confirmed diagnosis of stage 2-4 breast, prostate, or colorectal cancer, (OR) no prior history of cancer
* Stage 2-4 treatment naive, metastatic, secondary, and recurrent cancer patients
* Able to undergo blood collection prior to initiation of chemotherapy treatment, (OR) able to provide blood sample if subject is a non-cancer control subject
Exclusion Criteria
* Patients with known immunodeficiency, or pregnancy.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Commonwealth Hematology-Oncology, P.C.
UNKNOWN
Viatar LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pedro M Sanz-Altamira, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Commonwealth Hematology-Oncology, P.C.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Commonwealth Hematology-Oncology, P.C.
Lawrence, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T30-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.